Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Victoria S. Chua"'
Autor:
Sant P. Chawla, Steven Wong, Doris Quon, Ania Moradkhani, Victoria S. Chua, Don A. Brigham, Rebecca A Reed, William Swaney, Frederick L. Hall, Erlinda M. Gordon
Publikováno v:
Frontiers in Molecular Medicine, Vol 2 (2022)
Background: Innovative treatments are urgently needed for metastatic cancer. DeltaRex-G, a tumor-targeted retrovector encoding a dominant-negative/cytocidal cyclin G1 (CCNG1 gene) inhibitor construct—has been tested in over 280 cancer patients worl
Externí odkaz:
https://doaj.org/article/ec84daaadc184d128fc1926eced547a0
Autor:
Erlinda Maria Gordon, Sant P. Chawla, Walter Andree Tellez, Elan Younesi, Sonu Thomas, Victoria S. Chua-Alcala, Hripsime Chomoyan, Chrysler Valencia, Don Arlen Brigham, Ania Moradkhani, Doris Quon, Amornchit Srikureja, Steven G. Wong, William Tseng, Noah Federman
Publikováno v:
Cancers, Vol 15, Iss 3, p 906 (2023)
Background: This Phase 1/2 study is based on the hypothesis that immune checkpoint inhibitors are more effective when given earlier in the course of the disease for advanced soft tissue sarcoma. Methods: Phase I endpoints—maximum tolerated dose in
Externí odkaz:
https://doaj.org/article/59aa4d32c2804668b92adc9b9ba0343a
Autor:
ERLINDA M. GORDON, NICOLE L. ANGEL, NADEZHDA OMELCHENKO, VICTORIA S. CHUA-ALCALA, ANIA MORADKHANI, DORIS QUON, STEVEN WONG
Publikováno v:
Anticancer Research. 43:1993-2002
Autor:
Sant P. Chawla, Victoria S. Chua, Erlinda M. Gordon, John Cini, Susan Dexter, Manual DaFonseca, Justus Bingham, Grantham W. Hogeland, Richard T. Kenney
Publikováno v:
Cancer Research. 83:CT245-CT245
Recombinant interleukins (IL) have had limited clinical success due to inefficient tumor targeting and short pharmacokinetics (PK), requiring frequent dosing that leads to aberrant immunostimulation and toxicity. IL-12 is a promising cancer treatment
Autor:
Mrinal M. Gounder, Gary K. Schwartz, Robin L. Jones, Sant P. Chawla, Victoria S. Chua-Alcala, Silvia Stacchiotti, Andrew J. Wagner, Gregory M. Cote, Robert G. Maki, Hanna Kosela-Paterczyk, Dale R. Shepard, Naisargee Shah, Richard Bryce, Robert C. Doebele, Shreyaskumar Patel
Publikováno v:
Cancer Research. 82:CT235-CT235
Background: Murine double minute 2 (MDM2) is a negative regulator of tumor suppressor protein p53. MDM2 induces degradation of p53 and promotes tumorigenesis. MDM2 amplification occurs in many cancers but is documented in up to 100% of well-different
Autor:
Erlinda Maria Gordon, Victoria S. Chua-Alcala, Simranjit Sekhon, Noufil Adnan, Steve Wong, Doris V. Quon, Ania Moradkhani, Noah Federman, Don Arlen Brigham, Rebecca Reed, William Swaney, Frederick L. Hall, Sant P. Chawla
Publikováno v:
Journal of Clinical Oncology. 40:e15048-e15048
e15048 Background: Defects in cell cycle control are fundamental oncogenic drivers and targeting deregulated cell cycling is under intensive study. Cell cycle cyclin G1 (CCNG1) inhibitor therapy, exemplified by DeltaRex-G, a tumor-targeted retro vect
Autor:
Noufil Adnan, Simranjit Sekhon, Sant P. Chawla, Ted T. Kim, Victoria S. Chua-Alcala, Mitchel Fernando, Amir Ahari, William Feske, Doris V. Quon, Erlinda Maria Gordon
Publikováno v:
Journal of Clinical Oncology. 40:11518-11518
11518 Background: In our experience, combinatorial therapy with lower doses of doxorubicin, gemcitabine, and docetaxel has been effective with a manageable toxicity profile in patients with advanced soft tissue sarcomas. Hypothesis: The addition of n
Autor:
Victoria S. Chua-Alcala, Sant P. Chawla, Erlinda Maria Gordon, Ted T. Kim, Simranjit Sekhon, William Feske, Lucia Hui, Brenda L. Gibson, Paul Y Chang, Debra Robinson, Paul Y. Song
Publikováno v:
Journal of Clinical Oncology. 40:2644-2644
2644 Background: Natural killer (NK) cells play a key role as the main effector cells toward cancer in innate immunity. Thus, a leading approach is to boost NK-cell mediated anti-tumor activity using adoptive transfer of ex vivo activated NK cells. N
Autor:
Sant P. Chawla, Victoria S. Chua-Alcala, Erlinda Maria Gordon, Ted T. Kim, William Feske, Brenda L. Gibson, Paul Y Chang, Debra Robinson, Paul Y. Song
Publikováno v:
Journal of Clinical Oncology. 40:11517-11517
11517 Background: For patients (pts) with advanced sarcomas in the relapsed/refractory setting, there are very few if any effective salvage treatment options. The likelihood of response and/or tumor control only diminishes with each subsequent line o
Autor:
Sant P. Chawla, Ciara Marie Kelly, Erlinda Maria Gordon, Doris V. Quon, Ania Moradkhani, Victoria S. Chua-Alcala, Theresa M. Thompson, Anita Scheuber, Ingmar Bruns, Victoria E. Allgood, Sujana Movva
Publikováno v:
Journal of Clinical Oncology. 40:TPS11593-TPS11593
TPS11593 Background: Doxorubicin is a standard of care agent for patients with advanced soft tissue sarcoma, with a response rate of around 15%, progression-free survival of 5-7 months and cumulative cardiac toxicity that limits its use. TTI-621 is a